Navigation Links
Cardium Announces Investor Presentation and Corporate Update Webcast
Date:12/3/2008

SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) announces that the Company will be presenting a webcast providing an investor presentation, corporate update and review of its ongoing business strategies and plans. The webcast will be presented following the close of market today at 4:30 PM (Eastern Time) and can be accessed at http://www.investorcalendar.com/IC/CEPage.asp?ID=138418 at that time. The webcast will also be accessible for the following thirty days via the Investors section at "Calendar of Events" on the Company's website at http://www.cardiumthx.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

Forward-Looking Statements in Webcast

Except for statements of historical fact, the matters discussed in the webcast are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. Actual results may also differ substantially from those described in or contemplated by the webcast due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties inherent in the conduct of human clinical trials, including the timing, costs and results of such trials, our limited experience in the development, testing and marketing of therapeutic hypothermia devices, uncertainties regarding potential corporate development partners, our dependence upon proprietary technology, uncertainties regarding ongoing needs to support product development programs and other cash expenditures, our history of operating losses and accumulated deficits, risks and uncertainties related to our ability to raise cash under difficult capital market conditions, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2008 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit http://www.cardiumthx.com.

Cardium Therapeutics(TM) and Generx(TM) are trademarks of Cardium

                              Therapeutics, Inc.
Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM) and Excellarate(TM) are
                     trademarks of Tissue Repair Company.
       InnerCool Therapies(R), InnerCool(R), Celsius Control System(R),
  RapidBlue(TM), CoolBlue(TM), Accutrol(R), Temperature Control Element(R),
      TCE(R) and UroCool(TM) are trademarks of InnerCool Therapies, Inc.

'/>"/>
SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardium Completes $6.0 Million Financing
2. Cardium Announces InnerCools Endovascular Cooling to be Featured on Science Channels Series Cool Stuff: How It Works
3. Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
4. Cardium Reports on Recent Highlights and Financial Results
5. An international first at the CHUM - Promising treatment in regeneration of the myocardium through the use of stem cells
6. AANMA Announces Launch of Free Web-Based Education Program for Patients Transitioning From CFC to HFA Inhalers
7. Lucas Group Announces Their Executive Recruitment Military Hiring Conference Schedule for December 2008
8. Axiom Consulting Partners Announces the Results of its Return On Sales Investment Survey
9. United American Healthcare Corporation Announces Stock Repurchase Program
10. eOn Communications Announces GSA Contract
11. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: